April 12, 2026 11:04 pm (IST)
Follow us:
Pharma major Lupin completes its acquisition of US-based GAVIS
Mumbai, Mar 9 (IBNS): Pharma major Lupin Limited (Lupin) announced on Wednesday that it has completed its acquisition of privately held US-based GAVIS Pharmaceuticals LLC and Novel Laboratories Inc. (GAVIS).
Lupin had announced the acquisition on July 23, 2015.
The acquisition enhances Lupin’s scale in the US generic market and also broadens its pipeline in dermatology, controlled substance products and other high-value and niche generics.
The US-based manufacturing & research organization of GAVIS will complement Lupin’s Coral Springs, Florida based R&D center for Inhalation, according to the company.
GAVIS’s New Jersey based manufacturing facility also becomes Lupin’s first manufacturing site in the US.
New Jersey based GAVIS is a privately held company specializing in formulation development, manufacturing, packaging, sales, marketing, and distribution of pharmaceuticals products.
GAVIS has 62 ANDA filings pending approval with the US FDA and a pipeline of over 65+ products under development. 72% of these filings pending approvals represent niche dosage forms with 18 Para IVs and 8 FTFs products. GAVIS’s pending approvals address a market of over USD 9 billion.
The combined company will have a portfolio of over 120 in-market products, over 185 cumulative filings pending approval and a deep pipeline of products under development for the US.
The acquisition creates the fifth largest pipeline of ANDA filings with the US FDA, addressing a USD 63.8 billion market.
Lupin has 37 First-to-File (FTF) products, which includes 17 exclusive FTF opportunities.
Lupin and GAVIS combined would now have over 45 FTFs.
Commenting on the transaction, Vinita Gupta, Chief Executive Officer, Lupin Limited said, “We are very pleased to have completed our acquisition of Gavis. The Gavis portfolio augments our US business and niche generic pipeline. We plan to leverage the formulation expertise of Gavis to enhance both Lupin’s generic as well as specialty pipeline.”
Head-quartered in Mumbai, Lupin is a transnational pharmaceutical company producing and developing a wide range of branded and generic formulations, biotechnology products and APIs globally. The company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
Latest Headlines
Nissan Motor India marks major network expansion with 54 new customer touchpoints in Q1 of CY 2026
Fri, Apr 10 2026
Groww shares climb 5%, extend rally for third session
Fri, Apr 10 2026
From Oracle layoffs in the US to an India comeback: Couple’s emotional story goes viral
Fri, Apr 10 2026
South Asia remains fastest-growing region; India continues as growth engine: World Bank
Thu, Apr 09 2026
AI impact: Dell cuts 11,000 jobs in strategic workforce trim
Thu, Apr 09 2026
TCS gains ahead of Q4 earnings; street eyes growth signals
Thu, Apr 09 2026
Meesho shares soar 14% — stock now 55% above IPO price!
Thu, Apr 09 2026